Please assess the completion status of the following clinical trial:

Trial Title: The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. The body mass index is 18-28kg/m2 (including the critical value), which allows the minimum weight of men to be 50kg (including the critical value) and 45kg for women (including the critical value).~2. Before the study,participant has know about the significance , potential benefits, inconveniences and potential risks of the study~3. Participant has understood the research's procedure and sign the informed consent .~Exclusion Criteria:~* Participant who are Pregnancy, lactating women, and planned trials begin within six months of pregnancy~* Participant who has abnormal Physical examination, laboratory examination results and clinical significance (such as: liver function examination - aspartate aminotransferase (AST) and alanine aminotransferase (ALT) more than 1.5 times that of the upper limit of normal)~* Participant who has a history of cardiovascular, liver, kidney, digestive tract, nervous system, blood system, familial hematologic disease, abnormal thyroid function, or mental abnormality~* Participant who has drug allergy history and anaphylactic reaction~* Participant who took oral contraceptive in 6 months~* Participant who used any drug (including Chinese herbal medicine) within 1 week.~* Participant who donated blood within 2 months~* Participant who participated clinical trials of any drug in 3 months (as subjects)~* Participant who has any positive result of virus serology check: human immunodeficiency virus antigen antibody (HIV Ag/Ab) and hepatitis c virus (HCV) - immunoglobulin G(IgG) antibody to IgG, hepatitis b surface antigen (HBsAg) and treponema pallidum antibody (TP)~* Participant who are used to smoke, alcohol abuse, eat coffee and strong tea and drug abuse~* Participant who the researchers believe that there are volunteers who are not suitable for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SPH3127 100mg (Type: EXPERIMENTAL): A single dose of SPH3127 50 mg\*2 qd \*7 days
- Placebo to SPH3127 100mg (Type: PLACEBO_COMPARATOR): A single dose of placebo matching to SPH3127 50mg\*2 qd \*7 days
- SPH3127 200mg (Type: EXPERIMENTAL): A single dose of SPH3127 100 mg\*2 qd \*7 days
- Placebo to SPH3127 200mg (Type: PLACEBO_COMPARATOR): A single dose of placebo matching to SPH3127 100mg\*2 qd \*7 days
- SPH3127 400mg (Type: EXPERIMENTAL): A single dose of SPH3127 100 mg\*4 qd \*7 days
- Placebo to SPH3127 400mg (Type: PLACEBO_COMPARATOR): A single dose of placebo matching to SPH3127 100mg\*4 qd \*7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).